Table 3.
Overall meta-analysis results.
| Outcomes | WMD (95% Cl) | P | Test for heterogeneity | Analysis model | Sample size | Number of study | ||
|---|---|---|---|---|---|---|---|---|
| I2 (%) | P | Combination treatment | Tamsulosin monotherapy | |||||
| TIPSS | −1.650 (−2.617, −0.682) | 0.001 | 93.30% | 0.000 | R | 1,870 | 1,897 | 17 |
| SIPSS | −0.276 (−0.625, 0.073) | 0.121 | 73.50% | 0.000 | R | 998 | 995 | 7 |
| VIPSS | −0.311 (−0.655, 0.033) | 0.076 | 43.40% | 0.048 | F | 1,051 | 1,048 | 8 |
| QMAX | 1.270 (0.266, 2.274) | 0.013 | 93.20% | 0.000 | R | 1,052 | 981 | 13 |
| OABSS | −1.202 (−2.044, −0.361) | 0.005 | 95.60% | 0.000 | R | 613 | 647 | 7 |
| QOL | −0.382 (−0.746, −0.018) | 0.039 | 94.50% | 0.000 | R | 903 | 905 | 9 |
| PVR | 1.032 (−3.612, 5.676) | 0.663 | 79.70% | 0.000 | R | 1,057 | 959 | 9 |
| Urgency episodes per 24 h | 0.013 (−0.168, 0.194) | 0.888 | 42.00% | 0.069 | F | 1,186 | 1,083 | 6 |
| Micturitions per 24 h | 0.145 (−0.156, 0.445) | 0.345 | 56.30% | 0.019 | R | 1,006 | 996 | 5 |
| PSA | 0.192 (0.132, 0.253) | < 0.001 | 0.00% | 0.596 | F | 667 | 689 | 6 |
WMD, Weighted mean difference; CI, confidence interval; R, random effects model; F, fixed effects model; TIPSS, Total International Prostate Symptom Score; SIPSS, Storage International Prostate Symptom Score; VIPSS, Voiding International Prostate Symptom Score; QOL, Quality of life; QMAX, Maximal urinary flow rate; PVR, Post void residual volume; PSA, Prostate specific antigen; OABSS, Overactive bladder symptom score.
Bold values meant P-value < 0.05.